Cannell Capital’s Xilio Therapeutics XLO Stock Holding History

Cannell Capital’s Portfolio XLO Stock Details XLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,216	Closed	-$54K	–	84
2023 Q1	$54K	Hold	1,216	–	–	0.01%	70
2022 Q4	$45.8K	Hold	1,216	–	–	0.01%	70
2022 Q3	$50K	Buy	1,216 +891	+274%	+$34.6K	0.01%	68
2022 Q2	$13K	Buy	+325	New	+$17.2K	﹤0.01%	69

Other funds holding XLO

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RVM

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

TOCUITCONY

Trustees of Columbia University in the City of New York New York $891M AUM 17.3% 1-Year Est. Return

Cannell Capital's XLO Position: Q2 2023 in Review

Cannell Capital sold out of Xilio Therapeutics (XLO) in Q2 2023, closing a stake of 1,216 shares — an estimated $54K sold.

Cannell Capital first reported a position in XLO in Q2 2022 and held it in 4 quarters. The position peaked at $54K in Q1 2023. 32 funds tracked by Wall St. Rank hold XLO as of Q2 2023.

Cannell Capital reported no remaining Xilio Therapeutics position as of Q2 2023 after selling out during the quarter.
Cannell Capital sold 1,216 Xilio Therapeutics shares in Q2 2023, an estimated $54K.
Cannell Capital first reported a position in Xilio Therapeutics in Q2 2022 and held it in 4 quarters.
Cannell Capital's Xilio Therapeutics position peaked at $54K in Q1 2023.
32 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2023.

Based on Cannell Capital's 13F filing for Q2 2023, filed 14 Aug 2023.